Clinical Trials Logo

Glomerulonephritis, IGA clinical trials

View clinical trials related to Glomerulonephritis, IGA.

Filter by:

NCT ID: NCT01237028 Completed - IgA Nephropathy Clinical Trials

Additive Renoprotective Effects of Oral Calcitriol in IgA Nephropathy Patients Taking Renin-Angiotensin System Blockers

Start date: March 2011
Phase: N/A
Study type: Interventional

This study will help to show the efficacy of vitamin D and address the optimal strategy to minimize renal injury in IgAN patients.

NCT ID: NCT01225445 Completed - Clinical trials for Normal Blood Pressure

Treatment of Early Immunoglobulin A Nephropathy by Angiotensin Converting Enzyme Inhibitor - A Randomized Controlled Trial

Start date: April 2002
Phase: Phase 3
Study type: Interventional

Immunoglobulin A (IgA) nephropathy is the most common type of primary glomerulonephritis in the world. The treatment of IgA nephropathy with normal renal function and minimal proteinuria is unknown. Since angiotensin-converting enzyme (ACE) inhibitors reduce proteinuria and retard the rate of decline of renal function in chronic proteinuric nephropathies, including IgA nephropathy. The investigators conduct a randomized control study to evaluate the efficacy of ACE inhibitor in the treatment of early IgA nephropathy. Sixty patients with biopsy-proven IgA nephropathy and minimal proteinuria are recruited. They will be randomized to ramipril for 5 years or no treatment. Blood pressure, proteinuria and renal function will be monitored. This study will explore the effects of ACE inhibitor in the treatment of early IgA nephropathy, which is a major cause of dialysis-dependent renal failure.

NCT ID: NCT01224028 Completed - IgA Nephropathy Clinical Trials

A Study to Evaluate the Efficacy and Safety of Tacrolimus in Korean Nephropathy Patients

Start date: November 2010
Phase: Phase 2
Study type: Interventional

This study is to evaluate efficacy and safety of tacrolimus in the patients with non-nephrotic albuminuric, normotensive IgA nephropathy after 16 week treatment with tacrolimus (Prograf) or placebo.

NCT ID: NCT01203007 Not yet recruiting - IGA Nephropathy Clinical Trials

Diet Intervention in Food Sensitive Patients With IgA Nephropathy

DIIGA
Start date: September 2010
Phase: N/A
Study type: Interventional

The purpose of this study is to assess whether a tailored diet, eliminating antigens to which IgA nephropathy patients have demonstrated sensitivity, will have an effect on proteinuria, renal function and other immunological variables.

NCT ID: NCT01184599 Recruiting - Hypertension Clinical Trials

A Prospective Study of the Kidney Protective Effect of Aliskiren in Hypertensive Patients With IgA Nephropathy

Start date: June 2010
Phase: Phase 4
Study type: Interventional

The purpose of this study is to evaluate the effect of aliskiren, a novel direct rennin inhibitor, on renal function and progress of renal disease in hypertensive patients with IgA nephropathy.

NCT ID: NCT01129557 Terminated - Clinical trials for Diabetic Nephropathy

Aldosterone Breakthrough During Diovan, Tekturna, and Combination Therapy in Patients With Proteinuric Kidney Disease

Start date: September 2009
Phase: Phase 4
Study type: Interventional

Primary Hypothesis: Aldosterone breakthrough will occur at a far lower frequency during renin inhibition (0-10% over 9 months), alone or in combination with an ARB, compared to conventional ARB therapy (35-45% over 9 months). The investigators hypothesize that aldosterone breakthrough occurs due to accumulation of active precursor substances, most notably angiotensin II, produced in response to conventional RAAS blockade with ACEinhibitors and ARBs. The investigators believe that direct renin inhibition (DRI) should minimize this accumulation and therefore significantly lower or possibly eliminate the breakthrough effect. Interruption of the renin-angiotensin-aldosterone system (RAAS) with angiotensin-converting enzyme inhibitors (ACE-Is) and angiotensin receptor blockers (ARBs), alone and in combination, has become a leading therapy to slow the progression of chronic heart and kidney disease. Both types of drugs inhibit the formation of aldosterone, a hormone, which has been shown to have harmful effects on patients with chronic heart and kidney disorders. This treatment is effective but not perfect since, even after an initial improvement, many patients become worse over the long term. This may be due to an unexpected increase in aldosterone, a phenomenon called "aldosterone breakthrough." The purpose of this study is to find out whether the use of a direct renin inhibitor (DRI) alone, or in combination with an angiotensin receptor blocker (ARB), will lessen the occurrence of aldosterone breakthrough since direct renin inhibitors inhibit the formation of aldosterone at a very early step. This study will compare the effectiveness of adding Diovan (valsartan) or Tekturna (aliskiren) or a combination of Diovan and Tekturna to the usual antihypertensive treatment. The investigators will follow blood pressure, aldosterone levels, and urinary protein levels over 9 months to evaluate which of these therapies is most effective for treating hypertension in patients with proteinuric kidney disease.

NCT ID: NCT01115426 Completed - Clinical trials for IGA Glomerulonephritis

Inhibitors of Angiotensin II in Proteinuric Mesangioproliferative Glomerulonephritis

Start date: January 1997
Phase: Phase 4
Study type: Interventional

This study evaluates prospectively the effects of an anti-angiotensin II regimen on renal outcome in patients with mesangioproliferative glomerulonephritis followed-up for 10 years.

NCT ID: NCT01103778 Completed - Clinical trials for Chronic Kidney Disease

Pilot Study of Velcade® in IgA Nephropathy

Start date: July 2010
Phase: Phase 4
Study type: Interventional

The primary objective of this study is to investigate the ability of Velcade® (bortezomib) to induce complete or partial remission in patients with severe IgA nephropathy. The secondary objectives are to assess clinical outcomes relating to safety and efficacy, such as infection, malignancy, preservation of renal function, partial responders, relapse rate, and to study mechanistic assays to predict remission.

NCT ID: NCT00922311 Completed - IgA Nephropathy Clinical Trials

Aliskiren for Proteinuric IgAN Despite Angiotensin Blockade

Start date: July 2009
Phase: Phase 4
Study type: Interventional

Study objective: To investigate the potential anti-proteinuric efficacy of aliskiren, a novel direct renin inhibitor (DRI), in addition to angiotensin receptor blocker (ARB) in immunoglobulin A nephropathy (IgAN) patients at risk of developing progressive renal failure.

NCT ID: NCT00885547 Terminated - IgA Nephropathy Clinical Trials

Prospective Study of TW in Treatment of IgAN With Asymptomatic Abnormal Urinalysis

Start date: March 2009
Phase: N/A
Study type: Interventional

The purpose of this study is to: 1. To evaluate the latest effects of TW for IgA nephropathy (IgAN) with asymptomatic abnormal urinalysis. 2. To evaluate the safety and tolerability of TW.